Sangamo Therapeutics decides not to proceed with public offering; reaffirms cash runway

SANGAMO THERAPEUTICS, INC

Sangamo explored a potential public offering but chose not to move forward after evaluating market conditions and business outlook.
Company believes available cash, equivalents, and marketable securities will fund operations for at least 12 months from Dec 31, 2022 10-K.
Sangamo will continue to seek additional capital, including non-dilutive sources, and may pursue equity financing in the future.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.